Ani Pharmaceuticals has purchased four abbreviated new drug applications from Oakrum Pharma, a biopharmaceutical company.
Ani Pharmaceuticals is a biopharmaceutical firm that develops prescription pharmaceutical products.
“We are pleased to expand our generics product portfolio with the acquisition of four limited competition ANDAs. We expect to launch these products and see the value unlock in 2023. This transaction complements the investment and efforts of our internal research and development team to bring much-needed medicines to patients in need,” stated Nikhil Lalwani, CEO of Ani.
Bourne Partners served as financial advisor to Oakrum Pharma.